Recently it was shown that anti-CXCL13 antibody – blocking the main ligand for CXCR5 receptor – demonstrated efficacy at least in two experimental models of autoimmune disorders – the collagen-induced arthritis (a mouse model of RA) and passively-induced experimental autoimmune encephalomyelitis (a Th17-mediated murine model of multiple sclerosis)46. Here, CXCL13 is linked to rheumatoid arthritis.